University of Nebraska - Lincoln

DigitalCommons@University of Nebraska - Lincoln
Nutrition and Health Sciences -- Faculty
Publications

Nutrition and Health Sciences, Department of

4-23-2022

Does a Hypertrophying Muscle Fibre Reprogramme its
Metabolism Similar to a Cancer Cell?
Henning Wackerhage
Technical University of Munich

Ivan J. Vechetti
University of Nebraska-Lincoln

Philipp Baumert
Technical University of Munich

Sebastian Gehlert
University of Hildesheim

Lore Becker
German Research Center for Environmental Health

See next page for additional authors
Follow this and additional works at: https://digitalcommons.unl.edu/nutritionfacpub
Part of the Human and Clinical Nutrition Commons, Molecular, Genetic, and Biochemical Nutrition
Commons, and the Other Nutrition Commons

Wackerhage, Henning; Vechetti, Ivan J.; Baumert, Philipp; Gehlert, Sebastian; Becker, Lore; Jaspers,
Richard T.; and Hrabě de Angelis, Martin, "Does a Hypertrophying Muscle Fibre Reprogramme its
Metabolism Similar to a Cancer Cell?" (2022). Nutrition and Health Sciences -- Faculty Publications. 300.
https://digitalcommons.unl.edu/nutritionfacpub/300

This Article is brought to you for free and open access by the Nutrition and Health Sciences, Department of at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Nutrition and Health
Sciences -- Faculty Publications by an authorized administrator of DigitalCommons@University of Nebraska Lincoln.

Authors
Henning Wackerhage, Ivan J. Vechetti, Philipp Baumert, Sebastian Gehlert, Lore Becker, Richard T.
Jaspers, and Martin Hrabě de Angelis

This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/
nutritionfacpub/300

Sports Medicine (2022) 52:2569–2578
https://doi.org/10.1007/s40279-022-01676-1

CURRENT OPINION

Does a Hypertrophying Muscle Fibre Reprogramme its Metabolism
Similar to a Cancer Cell?
Henning Wackerhage1 · Ivan J. Vechetti2 · Philipp Baumert1 · Sebastian Gehlert3 · Lore Becker4 ·
Richard T. Jaspers5 · Martin Hrabě de Angelis4,6,7
Accepted: 17 March 2022 / Published online: 23 April 2022
© The Author(s) 2022

Abstract
In 1924, Otto Warburg asked “How does the metabolism of a growing tissue differ from that of a non-growing tissue?” Currently, we know that proliferating healthy and cancer cells reprogramme their metabolism. This typically includes increased
glucose uptake, glycolytic flux and lactate synthesis. A key function of this reprogramming is to channel glycolytic intermediates and other metabolites into anabolic reactions such as nucleotide-RNA/DNA synthesis, amino acid-protein synthesis and
the synthesis of, for example, acetyl and methyl groups for epigenetic modification. In this review, we discuss evidence that a
hypertrophying muscle similarly takes up more glucose and reprogrammes its metabolism to channel energy metabolites into
anabolic pathways. We specifically discuss the functions of the cancer-associated enzymes phosphoglycerate dehydrogenase
and pyruvate kinase muscle 2 in skeletal muscle. In addition, we ask whether increased glucose uptake by a hypertrophying
muscle explains why muscularity is often negatively associated with type 2 diabetes mellitus and obesity.
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Nearly 100 years ago, Otto Warburg discovered that
cancer cells reprogramme their metabolism by increasing glucose uptake and lactate synthesis in the presence
of oxygen, which is termed the Warburg effect.
Currently, we know that the metabolic reprogramming
in proliferating healthy and cancer cells helps to generate glycolytic intermediates and other metabolites as
substrates for anabolic reactions to build biomass.
Myc, hypoxia-induced factors and Pi3k–Akt–mTor not
only regulate metabolic reprogramming in cancer but are
also signalling molecules that are activated by resistance
training and stimulate muscle hypertrophy.
For every gram of biomass that a muscle builds, it needs
to take up 1 g of small-molecule substrates such as glucose, amino acids and other molecules. This uptake of
glucose and other metabolites may explain why muscular
organisms or resistance-trained individuals are often lean
and have good insulin sensitivity.
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1 Introduction
In 1924, Otto Warburg published a paper on the metabolism of cancer cells in Naturwissenschaften. In it, he
asked “How does the metabolism of a growing tissue
differ from that of a non-growing tissue?” [1]. In this
paper, Warburg demonstrated in vitro [1] and 3 years later
in vivo [2] that cancer cells reprogramme their metabolism. Key features of this metabolic reprogramming are
that cancer cells take up more glucose and synthesise
more lactate in the presence of oxygen than non-growing
cells and organs. Ephraim Racker later termed such aerobic glycolysis the “Warburg effect” to contrast it with the
“Pasteur effect,” which is anaerobic glycolysis [3].
In this review, we first discuss the Warburg effect in
cancer and how it helps to provide substrates for anabolism and for the generation of biomass. We then review
evidence that hypertrophying muscles reprogramme their
metabolism similarly to cancer cells. Third, we discuss
the potential benefits of such metabolic reprogramming
for the prevention and treatment of type 2 diabetes mellitus and obesity.

2 How Do Healthy and Cancerous
Proliferating Cells Reprogramme Their
Metabolism?
Most but not all healthy and cancerous proliferating cells
take up more glucose as well as synthesise more lactate
in the presence of oxygen than non-proliferating cells [4,
5]. Otto Warburg hypothesised that this was because of a
mitochondrial defect causing cancer cells to rely on glycolysis for ATP resynthesis [6]. However, many cancers have
functioning mitochondria [7] and thus a defective oxidative phosphorylation does not generally explain increased
glycolytic flux in cancer.
So, what is the Warburg effect good for? Otto Warburg
and subsequent scientists until the late 1990s were unable
to answer this question satisfactory. Research since then
has shown that a key function of the metabolic reprogramming in cancer is to generate glycolytic intermediates
and other energy metabolites as substrates for anabolism,
which is the part of metabolism that synthesises “cellular
components from precursors of low molecular weight”
(International Union of Pure and Applied Chemistry definition 1997). More specifically, proliferating cells take up
more glucose, glutamine [8] and other small molecules,
and then channel these molecules into glycolysis or other
energy metabolic reactions, which are “feeder pathways”
for anabolic reactions. These anabolic reactions include the
synthesis of nucleotides for DNA and RNA, the synthesis
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of non-essential amino acids for protein synthesis and the
synthesis of other macromolecules. How energy metabolism is connected to anabolism is for example illustrated by
the IUBMB-Nicholson Metabolic Pathways Chart [9]. An
overview over some key reactions involved in the metabolic
reprogramming of proliferating and/or growing cells is illustrated in Fig. 1.
More recent research shows that the metabolic reprogramming varies from cancer to cancer, suggesting that
it is not a rigid programme. For example, 149 out of 240
cancers overexpressed glycolytic genes [11]. In a more
comprehensive analysis from 2016, the researchers compared the expression of metabolic genes across 20 types of
cancer with their expression in the corresponding healthy
tissue. They found that 14 cancers (70%) overexpressed
purine synthesis genes, ten (50%) overexpressed DNA
synthesis genes, seven (35%) overexpressed oxidative
phosphorylation genes, and only five (25%) overexpressed
glycolysis and gluconeogenesis genes [12]. The limitation of these metabolic gene expression analyses is that
they depend on how the criteria for “overexpression” are
set and that they do not measure actual changes in metabolic flux in-between proliferating and non-proliferating
cells. Nonetheless, they suggest that the metabolic reprogramming of proliferating cells varies.
In summary, a key function of the metabolic reprogramming of proliferating cells is to provide substrates
for anabolic pathways that generate the biomass necessary for cell proliferation. Otto Warburg already in 1924
stated that such reprogramming was not unique to cancer but also occurred for example in the growing chick
embryo [13]. Several reviews discuss specific aspects of
metabolic reprogramming in cancer such as the regulation
of the metabolic reprogramming, the metabolic pathways
involved (Fig. 1), the function of metabolic reprogramming beyond energy metabolism and anabolism, research
methods to analyse metabolic reprogramming as well as
unanswered questions [4, 5, 14].

3 Is There Evidence That Metabolic
Reprogramming Occurs When Muscle
Fibre Hypertrophy?
Muscle fibres are, in contrast to proliferating cells, nonproliferating syncytia (i.e. multi-nuclear cells) with thousands of nuclei and muscle fibres can reach a length of up
to ≈ 20 cm in humans [15]. However, given that proliferating cells reprogramme their metabolism to channel more
energy metabolites into anabolism, and given that muscle
hypertrophy relies on anabolism, an intriguing question is:
Do hypertrophying, post-mitotic muscle fibres reprogramme
their metabolism similar to proliferating cells?
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Fig. 1  Schematic showing some connections in-between energy
metabolism and anabolism modified after [5]. In proliferating cells,
glycolysis is typically upregulated, and glycolytic intermediates and
other energy metabolites flow more into anabolic reactions such as
nucleotide-DNA/RNA synthesis (red), amino acid-protein synthesis
(blue), lipid synthesis (purple) and the synthesis of small groups used
for epigenetic modification (green). Note that not only glucose but

also glutamine is taken up at a high rate by rapidly proliferating cells
[8, 10]. For further information, for example, on substrate synthesis
for epigenetic modification, see DeBerardinis and Chandel [5]. CTP
cytosine triphosphate, GTP guanosine triphosphate, P phosphate,
Phgdh phosphoglycerate dehydrogenase, Pkm1/2 pyruvate kinase
muscle isoforms 1 and 2, TTP thymine triphosphate, UTP uracil
triphosphate

Before answering this question, we highlight a key difference in terms of anabolism between proliferating cells and
hypertrophying muscle fibres. Proliferating cells need to replicate their entire genome during each cell cycle. This means
that each proliferating human cell will synthesise 6.4 billion
nucleotides plus nucleotides for mRNA and ribosomal biogenesis before dividing into two daughter cells. In contrast,
a hypertrophying muscle fibre “only” synthesises nucleotides for mRNA and ribosome biogenesis [16] as it has “outsourced” replication and the generation of new myonuclei to
proliferating satellite cells. The fact that ribose, the pentose
sugar in RNA, and deoxyribose, the pentose sugar in DNA,
are primarily synthesised from glucose [17] is one reason for
why proliferating cells take up more glucose. However, the
ribosome biogenesis of hypertrophying muscle fibres [16]
will also require glucose to synthesise the nucleotides and
rRNA from which ribosomes are made. Hosios et al. have
directly compared the contribution of radioactive or stable
isotope tracers such as 14C/13C-glucose or 14C/13C-glutamine
to the cell mass of proliferating C2C12 myoblasts and differentiated C2C12 myotubes [10]. They found that glucose and
glutamine contributed 15% and 8% to cell mass in proliferating C2C12 myoblasts in a steady state and 6% and 3% to cell
mass in differentiated but not hypertrophy-stimulated C2C12

myotubes after 6 days of incubation, respectively [10]. In
summary, proliferating and hypertrophying cells both generate biomass via anabolic reactions but only proliferating
cells synthesise DNA for replication.
Back to the question whether hypertrophying post-mitotic
muscle fibres reprogramme their metabolism similar to proliferating cells. First, indirect evidence for metabolic reprogramming during muscle hypertrophy comes from studies
that show that cancer metabolic reprogramming factors
such as the transcription factor Myc [18] and hypoxiainduced factors, which typically regulate glycolytic genes
[19], become more expressed in overloaded hypertrophying
mouse muscle (Myc and Hif1a [20]) or in human muscle
after a bout of resistance exercise (MYC and EPAS1 [21]).
Moreover, Pi3k–Akt–mTor signalling, which also regulates
metabolic reprogramming in cancer [5], is activated as
judged by the phosphorylation of mTORC1 proteins such
as S6K1 [22–25]. However, whilst for example Myc drives
the expression of lactate dehydrogenase A (gene Ldha) in
cancer, only MYC expression but not LDHA expression
increases in human muscle after resistance exercise [21].
Although MYC is probably not a driver of LDHA expression in human muscle, adeno-associated mediated Myc
overexpression in the mouse gastrocnemius is sufficient
for ribosomal biogenesis and increased protein synthesis
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[26]. As ribosomes comprise ≈ 60% rRNA, this requires
first synthesising nucleotides from a purine or pyrimidine,
sugar and phosphate followed by rRNA biosynthesis and
ribosome biogenesis. This requires the regulation of metabolic pathways such as the pentose phosphate pathway. In
summary, regulatory molecules such as Myc, Hif proteins
and Pi3k–Akt–mTor signalling become more expressed or
activated after resistance training. Especially for Myc and
Pi3k–Akt–mTor signalling (see below), there is evidence
that this also reprogrammes the metabolism of hypertrophying muscle fibres.
Second, inhibiting glycolysis with 500 mg/kg of 2-deoxyglucose reduces basal protein synthesis of untreated and
electrically stimulated rat gastrocnemius muscle 6 h after
stimulation when compared with untreated controls [27].
This suggests that glycolytic flux limits protein synthesis,
which is the primary cause of muscle hypertrophy.
Further evidence for the idea that hypertrophying myotubes reprogramme their metabolism comes from a study
where the researchers compared cultured control myotubes to insulin-like growth factor (IGF-1)-transfected
myotubes. The IGF-1-transfected C2C12 myotubes had a
2.7-fold higher rate of protein synthesis and were > 50%
wider than control myotubes, indicating that IGF-1 had
stimulated myotube hypertrophy. The activity of lactate
dehydrogenase (gene Ldh) in the IGF-1-transfected myotubes was 3.2 times higher and the concentration of lactate
was 2.4 times higher than in the control myotubes [28],
suggesting that a Warburg-like metabolic reprogramming was triggered by IGF-1. Moreover, IGF-1 activates
the Pi3k–Akt–mTor pathway, which helps to reprogramme
metabolism in cancer [5]. Muscle hypertrophy achieved by
synergist ablation also increases glycolytic flux by ≈ 60%
in the absence of insulin in overloaded incubated soleus
muscles when compared with control solei [29]. In a more
recent publication, the authors confirmed that an overload
roughly doubled plantaris glucose uptake, increased lactate secretion by ≈ 50% (but no effect on glycolytic flux)
and activated the pentose phosphate pathway as evidenced
for example by increased glucose-6 phosphate dehydrogenase protein levels [30]. Moreover, we recently demonstrated that the expression of G6pd, which encodes glucose-6 phosphate dehydrogenase, the rate-limiting gene
of the pentose phosphate pathway, is upregulated together
with other genes of the pentose phosphate pathway in
mechanically overloaded mouse plantaris muscles [31].
The pentose phosphate pathway is active in cancer [32]
and synthesises nucleotides for DNA, RNA and ribosome
biogenesis (ribosomes primarily consist of ribosomal
RNA).
Akt1 is a serine/threonine kinase and member of the
Pi3k–Akt–mTor pathway. In vivo, inducing the expression of
constitutive active Akt1 in mouse muscle for 2 weeks nearly
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doubled mean type 2B muscle fibre size from 1406 ± 21 µm2
to 2788 ± 139 µm2 [33]. The muscles of these mice also
expressed more hexokinase (gene Hk2), phosphofructokinase (gene Pfk), lactate dehydrogenase (gene Ldha) and the
cancer-specific isoform 2 of pyruvate kinase (gene Pkm2)
[33, 34].
Additional supporting evidence that Pi3k–Akt–mTor signalling not only promotes muscle hypertrophy but also metabolic reprogramming comes from mice where the mTORC1
inhibitor Nitrogen Permease Regulator 2-Like Protein
(Nprl2) is knocked out. Again, this causes muscle fibre
hypertrophy and induces aerobic glycolysis as judged by a
three-fold higher expression of Slc2a1, which encodes the
glucose transporter Glut1, and two-fold higher expressions
of Hk2, encoding hexokinase 2, and LdhB, encoding lactate
dehydrogenase B. Moreover, many amino acid metabolismregulating genes change their expression in muscles of Nprl2
knock-out mice [35].
Finally, inhibiting mTORC1 with rapamycin (termed
everolimus in this paper [36]) in C2C12 myotubes changed
the concentrations of many glycolytic intermediates and of
metabolites of the pentose phosphate pathway. Moreover,
rapamycin reduced the expression of glucose handling and
glycolytic genes such as Slc2a1 and Hk1, which encode
hexokinase 1, and Pfkm1, which encodes the rate-limiting
enzyme of glycolysis, phosphofructokinase. Collectively, the
metabolomics, gene expression and enzyme activity analyses
suggest that mTORC1 blockage with rapamycin causes the
opposite of a cancer-like metabolic reprogramming [36].
However, metabolic reprogramming during muscle
hypertrophy is not only induced by IGF-1–Pi3k–Akt–mTor
signalling. For example, Mstn knockout mice have more
type 2B fibres and an increased glycolytic capacity [37]. It
is unclear how these hypertrophy regulators modulate the
fibre-type distribution and whether the increased expression
of glycolytic enzymes is due to the induction of a Warburg
effect-related gene expression or simply due to a slow-to-fast
muscle fibre type shift. Interestingly, more glycolytic type
2 muscle fibres also hypertrophy to a greater extent than
less glycolytic type 1 muscle fibres after resistance exercise
[38]. Moreover, the inverse relationship between oxidative
metabolism and muscle fibre size as shown between muscle
fibres within a muscle as well as between fibres of different
species [39] indicates a tight association between muscle
size and glycolytic and oxidative metabolism. Paradoxically, slow high oxidative muscles possess a higher content
of components of the protein synthesis machinery (i.e. a
higher content of myonuclear density and ribosomes) than
fast glycolytic muscle fibres [39, 40]. Despite the lower
potential for protein synthesis, the hypertrophic potential
of fast glycolytic muscle fibres is higher and currently there
is no satisfactory explanation for this [39]. One hypothesis
could be that the higher glycolytic capacity of type 2 fibres
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increases the capacity for a Warburg-like metabolic reprogramming, and thereby facilitates muscle hypertrophy.
Another study investigated the effect of testosterone, a
male sex hormone that increases muscle fibre size [41],
on rat myotubes. Testosterone induced hypertrophy and
increased the activity of the glycolytic enzymes hexokinase and phosphofructokinase in a dose-dependent manner [42], again consistent with a Warburg-like metabolic
reprogramming.
In our own research, we have studied two enzymes associated with metabolic reprogramming in cancer. The first is
pyruvate kinase muscle (gene PKM; EC 2.7.1.40), which
catalyses the last step of glycolysis from phosphoenolpyruvate to pyruvate. PKM is alternatively spliced into Pkm1 and
Pkm2 variants. Pkm2 is especially expressed in cancer and
proliferating cells and has non-glycolytic regulatory functions [43]. Alternative Pkm splicing also occurs in skeletal
muscle. For example, embryonal muscle expresses Pkm2,
which is associated with proliferation [44] and then shifts
to Pkm1 in adult muscle [45]. In vitro, the knock down of
Pkm2 reduces myotube size whereas the knock down of
Pkm1 increases C2C12 myotube size, suggesting that a
high Pkm2/Pkm1 ratio promotes myotube hypertrophy [46].
However, we know little about how Pkm splicing and activity are regulated in a hypertrophying muscle. A phosphoproteomics study has revealed that Pkm is phosphorylated at
multiple sites in skeletal muscle [23] and we found that the
PKM2 isoform is more expressed in fast glycolytic muscle
fibres and increases after weeks of resistance training [46].
Moreover, reducing Pkm2 by shRNA or the Pkm2 inhibitor shikonin in C2C12 myoblasts reduced C2C12 myoblast
proliferation, but knocking out Pkm2 in Pax7-positive satellite cells did not impair regeneration after a muscle injury
[44]. Together this suggests that the Pkm2 isoform can help
to promote anabolism.
A second enzyme that is associated with metabolic reprogramming in cancer is Phgdh (EC 1.1.1.95). It diverts the
glycolytic metabolite 3-phospho-d-glycerate from energy
metabolism into the serine biosynthesis pathway. An unbiased RNA interference screen of metabolic genes has identified Phgdh as an enzyme that limits proliferation of breast
cancer cells [47]. In muscle, Phgdh expression increases
in mouse muscle that hypertrophies after synergist ablation [20, 31]. Phgdh expression also transiently increases in
response to β2-agonist stimulation [48] but not after human
resistance exercise [21]. In vitro, Phgdh knock down reduces
C2C12 myotube size, suggesting that the increased Phgdh
activity promotes hypertrophy [49].
Finally, Japanese researchers have characterised the
metabolome, gene expression and proteome response of
C2C12 myotubes to 2-Hz and 20-Hz electrical pulse stimulations. In this model, 20-Hz stimulation is presumably a
model for resistance exercise-induced muscle hypertrophy.
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The combined data suggest that 20-Hz stimulation activated
the pentose phosphate pathway, which helps to synthesise
nucleotides for RNA and DNA synthesis. Again, this suggests a metabolic reprogramming that goes beyond energy
metabolism [50].
Taken together, there is scientific “smoke” that a Warburg
effect-like metabolic reprogramming occurs at least in some
models of skeletal muscle hypertrophy. Whilst there is no
general upregulation of glycolytic and cancer metabolismassociated genes in a resistance-trained human muscle [21],
in some situations, glycolytic enzyme expression increases
and some cancer reprogramming-associated genes such as
Pkm2 and Phgdh can limit muscle hypertrophy. Furthermore, each kilogram of fat-free, human muscle dry mass
comprises ≈ 715 g of protein, ≈ 4 g of RNA, ≈ 2 g of DNA
[51] and consequently ≈ 279 g of other molecules such as
phospholipids in membranes. Thus, whilst nucleotide synthesis must occur for ribosome biogenesis [16] and whilst
proliferating satellite cells will synthesise nucleotides for
replication, the quantitatively most important biomass-generating process will be protein synthesis from amino acids
that are taken up or that are synthesised by the muscle fibre
from precursors.
Researchers should now use the full tool kit of modern
metabolic research to quantitatively characterise the metabolic reprogramming that occurs during muscle hypertrophy.
Importantly, researchers should verify that the metabolic
reprogramming during muscle hypertrophy is not just an
adaptation of energy metabolism but that it serves functions such as synthesising substrates for anabolic reactions
as in cancer [5]. Finally, we have not discussed the metabolic reprogramming of proliferating satellite cells [52] in
a hypertrophying muscle as satellite cells only contribute a
small fraction of the volume of a muscle.

4 Does Metabolic Reprogramming During
Muscle Hypertrophy Affect Our Health?
A high glucose uptake by tumour cells was one of the key
original observations of Otto Warburg [1, 2, 53]. In relation
to muscle hypertrophy, the question arises: does a hypertrophying muscle fibre similarly take up more glucose and
does it channel some of that glucose into anabolic reactions?
If that was the case, then muscle hypertrophy should have
positive health effects because a higher glucose uptake by
hypertrophying muscles would improve glycaemic control
and reduce the amount of glucose available for lipid synthesis by adipose tissue. If these reactions removed a sufficiently high amount of glucose and other small molecules
from the circulation, then muscle hypertrophy could help to
prevent or treat diabetes and obesity.
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There is indeed evidence that hypertrophying muscles take
up more glucose and that this improves glycaemic control and
reduces white adipose tissue. Figure 2A shows the 18F-fluoro2-deoxy-d-glucose positron emission tomography scan of a
patient who had performed “strenuous upper limbs exercise
[presumably resistance exercise] 24 h prior to the imaging”.
The scan suggests that the pectoralis muscle of the patient
takes up a high amount of glucose 1-day post-exercise [54].
The caveat, however, is that we are unable to say whether
the taken-up glucose is channelled into anabolism or is simply used to resynthesise the glycogen that was used during
exercise. In another study, a Copenhagen team asked healthy
and type-2 diabetic volunteers to perform a 6-week, one-sided
leg resistance training. After the training, they performed an
isoglycaemic-hyperinsulinemic clamp procedure and found
that the resistance-trained leg took up ≈ 25% (healthy) and
≈ 10% more glucose (type 2 diabetes, both p > 0.05) than the
untrained leg [55]. Moreover, in mice, synergist ablationinduced soleus hypertrophy increased both glucose uptake
and glycolytic flux in lean (especially at insulin concentrations < 5 nmol/L) and obese mice at all insulin concentrations when compared with the untreated control soleus [29].
Additionally, overloaded, hypertrophying mouse plantaris
muscles take up ≈ 60% more glucose than control plantaris.
In Slc2a4 (encoding the glucose transporter Glut4) knock-out
mice, the difference is even greater, as the glucose uptake of
the hypertrophying plantaris is similar to the wild-type hypertrophying plantaris but glucose uptake into the non-hypertrophying control plantaris is decreased [56]. Collectively, these
studies suggest that resistance-trained and/or hypertrophying mouse and human muscles take up more glucose than
untrained or non-hypertrophying muscles. But why? Is it just

to replenish glycogen or is a fraction of the glucose channelled
into anabolism?
To specifically test whether muscle can channel glucose
into anabolism and specifically amino acid and protein
synthesis, we incubated C2C12 myotubes with radioactive
14
C-glucose, extracted protein and used a scintillation counter
to investigate whether 14C in glucose can be incorporated into
protein. This experiment confirmed that glucose-derived 14C
can be incorporated into muscle protein and that hypertrophy
stimulation by IGF-1 increases the rate of 14C incorporation
into protein presumably via an 14C-glucose → 14C-glycolytic
intermediate → 14C-non-essential amino acid → 14C-protein
pathway. Conversely, inhibiting mTORC1 with rapamycin
reduced 14C incorporation into protein ([49] Fig. 2B). The
fact that C2C12 myotubes can incorporate glucose-derived
carbon into cell mass was also observed in another study [10].
In summary, hypertrophying muscles take up glucose for at
least 1 day after a bout of resistance exercise and the stimulation of hypertrophy by IGF-1 increases the incorporation of
14
C from glucose into myotube protein, which is consistent
with the idea that a hypertrophying muscle channels more
glucose and energy metabolites into anabolism.
Does a Warburg-like metabolic reprogramming of hypertrophying muscles improve insulin resistance? If resistance
exercise stimulated glucose uptake to channel glucosederived energy metabolites into anabolism, then resistance
exercise should improve insulin resistance. Indeed, metaanalyses conclude that resistance training improves glycaemic control in individuals at risk for diabetes [57] and in
patients with type 2 diabetes [58]. However, it is unclear
whether the glycaemia-improving effects are explained fully
by increased glycogen resynthesis or whether some of that

Fig. 2  A Fluorodeoxyglucose uptake of a pectoralis muscle 24 h
after strenuous upper limb exercise [54]. B Incorporation of glucosederived 14C into muscle protein. In this experiment, we incubated
C2C12 myotubes with radioactive 14C-glucose and treated them with
combinations of 100 ng mL−1 of insulin-like growth factor (IGF-1) or

100 ng mL−1 of rapamycin. We observed that 14C from glucose ended
up in protein and that IGF-1 increased the incorporation of 14C into
protein significantly by ≈ 71% [49]. Note that the data in B are from a
not yet peer-reviewed preprint [49]. CPM counts per minute
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glucose is channelled into anabolism. Several studies suggest
that muscle hypertrophy not triggered by glycogen-reducing
exercise can increase glucose uptake and that this is antidiabetic. First, testosterone stimulates GLUT4 expression
and GLUT4 membrane localisation in cultured primary rat
myotubes [42]. This should increase glucose uptake, too, but
the authors did not measure this. Second, myostatin receptor
inhibition not only increased muscle mass but also prevents
diabetes in A-ZIP/F1 mice that normally develop diabetes
[59]. Third, inducing muscle hypertrophy by expressing constitutively active Akt1 in muscle prevented elevated blood
glucose and insulin concentrations in mice on a high-fat
and high-sugar diet, again demonstrating the anti-diabetic
effects of muscle hypertrophy [33]. In summary, muscle
hypertrophy improves glycaemia even if it is not triggered
by glycogen-reducing resistance exercise.
Does a Warburg-like metabolic reprogramming of hypertrophying muscles have an anti-obesity effect? If hypertrophying muscles
take up more glucose (Fig. 2A), then less glucose is available for
lipid de novo biosynthesis by white adipose tissue. As a consequence, organisms with hypertrophying muscles should be leaner
than organisms where muscle mass does not change or declines.
This is often the case. For example, mice with muscle hypertrophy

due to Akt1 gain-of-function [60] or myostatin loss-of-function
[61] mutations are leaner than controls with normal muscle mass.
Moreover, hypogonadal or castrated men are typically less muscular
but have more adipose tissue and more frequently develop insulin
resistance than non-hypogonadal men (Fig. 3 [62, 63]).
There is some evidence that this is also true for humans
as a “myostatin boy” was not only more muscular but also
appeared leaner than boys of a similar age [65]. Another study
has shown that the induction of Akt1-induced hypertrophy in
mice on a high-fat and high-sugar diet reduces fat and body
mass [33]. Finally, treating obese older men with the hypertrophy-inducing anabolic steroids [41] decreases abdominal fat
[66]. Indirect evidence comes from a systematic review that
found that resistance training which induces muscle hypertrophy reduced fat percentage by 1.46% (confidence interval − 1.78 to − 1.14, p < 0.0001), body fat mass by 550 g (confidence interval − 750 to ≥ 340) as well as visceral fat [67].
More generally, individuals are commonly leaner when their
muscles grow or when muscle mass is high (e.g. adolescents,
young adults, bodybuilders) than when muscle mass is stable, low or declines (e.g. sarcopenic or testosterone-deficient
individuals [68]). This is an observation with many caveats
but worth exploring more systematically. Collectively, these

Fig. 3  Indirect evidence for an association between muscle hypertrophy and low adiposity. A Loss of fat pads in mice with muscle hypertrophy where a muscle-specific HSA promoter drives the expression
of constitutive Akt1-Egfp in muscle fibres. Even though the transgene
is expressed in muscle, inguinal fat pads are lost [60]. B Belgian Blue
bull with muscle hypertrophy due to a 11-nucleotide deletion of the
Mstn gene that encodes the muscle mass inhibitor myostatin. Note
the low amount of subcutaneous fat, suggesting again an association
between muscle hypertrophy and low fat mass [64]. C Image of two
monozygous twins where the right twin has hypogonadism because

of a pituicytoma. The right twin had “proximal muscle wasting” but
more body fat when compared with the unaffected twin on the left,
again suggesting an inverse relation between muscle mass and fat
mass [62]. D, E Schematic of a hypothesis explaining why muscle
hypertrophy may result in leanness. When compared with muscles of
normal size (E), more glucose and other small molecules are taken up
by hypertrophying muscle and thus there is less glucose for triglyceride (fat) synthesis in white adipose tissue. This could possibly explain
the effect of muscle hypertrophy on adipose tissue mass
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observations suggest that muscle hypertrophy per se reduces
white adipose tissue mass. It remains to be uncovered whether
this is due to the metabolic reprogramming and elevated glucose and other small molecule uptake of hypertrophying muscles, which leaves less glucose for lipid synthesis by white
adipose tissue. In addition, it has to be evaluated how the ageing process itself influences these reprogramming capacities.
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5 Summary and Conclusions
In this review, we discussed how proliferating, healthy
and cancer cells reprogramme their metabolism to channel energy metabolites into anabolic reactions and provide
substrates for epigenetic reactions such as methylation or
acetylation. We also provided evidence that a hypertrophying muscle takes up more glucose and reprogrammes its
metabolism, too, and that part of that glucose is diverted
into anabolic pathways. Finally, we discussed evidence that
hypertrophying muscles take up more glucose and other
small molecules and that this can have anti-diabetic and
anti-obesity effects. Importantly, muscle hypertrophy can
have insulin resistance-improving and anti-obesity effects
even if it is not triggered by glycogen-decreasing resistance
exercise.
Key questions for future research are:
1. How does glucose uptake, flux and incorporation into
biomass differ in-between a hypertrophying and nonhypertrophying skeletal muscle fibre?
2. Are anabolic treatments (resistance training, drugs)
effective treatments for obesity and insulin resistance?
3. Is there an interconnected ageing triad of muscle atrophy
(sarcopenia), hyperglycaemia and weight gain/obesity?
4. Do distinct muscle hypertrophy models differentially
reprogramme energy metabolism and anabolism or is
there a common metabolic muscle hypertrophy programme?
5. What signal transduction events are required for reprogramming metabolic genes in a hypertrophying skeletal
muscle?
6. What energy metabolism enzymes or transporters limit
muscle hypertrophy?
7. How much do circulating molecules such as glucose,
glutamate and lactate contribute quantitatively to biomass in a hypertrophying muscle [10]?
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